Building Bridges: Research Canada Member Networking Event
Research Canada Member Networking Event
Wednesday, November 10, 2021 | 1:30 – 3:00 PM EST
During the pandemic, collaborative relationships built on mutual trust have accelerated and reached new levels of partnership as all stakeholders have gained a real sense that “we are in this together.”
The long road to mRNA vaccines is paved with decades of fundamental and applied research within academe. Along with the creation of new technologies through small biotechnology and biopharmaceutical companies aided by the marketing and manufacturing muscle of big pharma and the courage of patients who undergo clinical trials, these vaccines were made possible. The academic, biotechnology and biopharmaceutical sectors have pulled together and patients have stepped up in the face of the pandemic. Through the diversity of what each sector brings to the table, they have collectively saved the day!
Join us for this first in a series of Building Bridges Research Canada Member Networking events where, in the first half of the event, we’ll be joined by Cole Pinnow, President of Pfizer Canada and Dr. Uwe Schoenbeck, Senior Vice President and Chief Scientific Officer of Pfizer’s Emerging Science and Innovation global team who will speak about Pfizer’s partnership model and how they collaborated with BioNTech to develop one of the four COVID-19 vaccines currently approved by Health Canada. We hope that Mr. Pinnow and Dr. Schoenbeck will inspire you, in the second half of our event, to build bridges with your colleagues in other sectors.
With Guest Speakers:
Cole Pinnow was appointed President of Pfizer Canada on January 6, 2020. Prior to joining the Canadian organization in 2018, Cole was Vice President and Lead of Pfizer’s Alternate Site organization with responsibility for the Pfizer Essential Health business in the U.S. nonacute market. Before his appointment as President, Mr. Pinnow was the Canada Lead for Pfizer’s Hospital business.
Uwe Schoenbeck, PhD
Senior Vice President and Chief Scientific Officer
Emerging Science & Innovation (ES&I)
Pfizer Worldwide Research, Development, and Medical
Uwe Schoenbeck leads Pfizer’s Emerging Science & Innovation (ES&I) team. Part of Worldwide Research, Development & Medical, ES&I is charged with enhancing Pfizer’s pipeline through translation of external emerging science into breakthrough therapies for patients. Through the dedicated outreach to academia, consortia and Biotech via its Emerging Science Liaisons located around the globe ES&I works across Pfizer’s Therapeutic Areas to harnesses external cutting edge preclinical assets and breakthrough technologies applying a broad range of partnering vehicles, including research collaborations, consortia, licensing, acquisitions. With its Pfizer Innovation team ES&I also engages in equity investments as well as Seed investments and formation of new companies. Its Target Science team is focused on novel target and biology discovery research to
introduce differentiated First-in-Class programs with enhanced confidence in rationale into the WRD portfolio. And through its Centers for Therapeutic Innovation (CTI) ES&I prosecutes cutting edge science sourced from leading academic and medical centers globally, working in close partnership with external PIs and building an exciting pipeline across the range of Pfizer’s core areas. This end-to-end innovation capability aims to strengthen Pfizer’s research engine and provide key drivers for a pipeline of truly differentiated first-in-class assets as well as breakthrough technologies by effectively combining external innovation with internal drug development capabilities.
Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team. Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women’s Hospital, Harvard Medical School. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular & cell biology, cardiovascular research, immunology, and metabolism